Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

开始日期2025-05-06

申办/合作机构

The University of Alabama at Birmingham

[+1]

CTRI/2022/01/039430

/ Recruiting临床3期IIT

Triple Arm Randomised Controlled Trial Comparing Metronidazole, Tinidazole And Secnidazole For The Efficacy In The Patients Of Amoebic Liver Abscess (TARMENTS TRIAL) - TARMENTS Trial

开始日期2022-01-31

申办/合作机构-

NCT05033743

/ Completed临床2/3期IIT

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.

开始日期2021-07-09

申办/合作机构

Indiana University

[+1]

100 项与塞克硝唑相关的临床结果

登录后查看更多信息

100 项与塞克硝唑相关的转化医学

登录后查看更多信息

100 项与塞克硝唑相关的专利（医药）

登录后查看更多信息

325

项与塞克硝唑相关的文献（医药）

2025-12-01·FOOD CHEMISTRY

Design of sulfonic acid-functionalized hyper cross-linked polymer as a mixed-mode sorbent for nitroimidazoles detection

Article

作者: Wang, Juntao ; Ma, Ruiyang ; Guo, Yaxing ; Zhang, Fuyuan ; Jafari, Seid Mahdi

Accurate monitoring of nitroimidazole antibiotics (NDZs) in environmental and food matrices is critical for safeguarding public health and food safety. In this study, a novel sulfonic acid-functionalized hyper-cross-linked polymer (NDF-TPE-HCP) was synthesized via Friedel-Crafts alkylation reaction. The polymer exhibited unique mixed-mode interactions, which enabled efficient extraction of NDZs. Leveraging its strong ExEf, NDF-TPE-HCP was integrated into a solid-phase extraction system coupled with HPLC for the analysis of NDZs (metronidazole, ronidazole, secnidazole, dimetridazole and ornidazole) in water and fish muscle. The developed method demonstrated a good linearity with NDZs concentrations from 0.07 to 400 ng/g (or ng/mL) with the correlation coefficients (R²) ≥ 0.9972. Moreover, low limits of detection for the analytes (0.02-5.00 ng/g (or ng/mL)) were achieved. The method recoveries ranged from 85.2 % to 118.0 %, with the relative standard deviation (RSD) ≤ 9.8 %. The NDF-TPE-HCP based method can serve as a robust and sensitive tool for monitoring NDZs residues.

2025-12-01·ACTA PARASITOLOGICA

A Systematic Review about the Efficacy of Antiparasitic Agents in the Treatment of Blastocystis Species

Review

作者: Aral Akarsu, Gülay ; Ulusan Bağcı, Özlem

PURPOSE:

Blastocystis spp. is the most commonly identified protozoan in humans, yet its clinical significance and pathogenicity remain controversial. While often asymptomatic, it has been associated with gastrointestinal symptoms and urticaria. Metronidazole is the most frequently used first-line treatment; however, increasing reports of resistance and treatment failure have led to growing interest in alternative therapeutic options.

METHODS:

In this systematic review, we searched the Web of Science, Scopus, and PubMed databases using relevant keywords in article titles to identify studies related to the treatment of Blastocystis spp.

RESULTS:

A total of 195 records were retrieved. After removing duplicates and applying inclusion and exclusion criteria, 39 studies were deemed eligible. Data extracted included author, publication year, country, number of participants or samples, diagnostic method, subtype, treatment agent, dosage, intervention details, and clinical and parasitological outcomes. Of the included studies, 17 were human studies (14 clinical trials and 3 case reports), and 22 were in vitro or animal studies.

CONCLUSION:

Our findings suggest that metronidazole may be inappropriate as a first-line treatment, as it can increase the number of viable parasites and promote their transformation into apoptosis-resistant granular or more pathogenic amoeboid forms. Alternative agents-such as ronidazole, satranidazole, and C17 (2-position 5-nitroimidazoles), as well as ornidazole, secnidazole, and tinidazole (1-position 5-nitroimidazoles with different side chains compared with metronidazole)-show potential efficacy. Trimethoprim-sulfamethoxazole and nitazoxanide have also demonstrated promising results. Further studies, particularly subtype-specific and human clinical trials, are needed to assess the safety and efficacy of these alternative agents against Blastocystis spp.

2025-10-01·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Preparation and characterization of a secnidazole-mandelic acid coamorphous system: enhanced dissolution profile, antibacterial properties, and theoretical druglikeness assessment

Article

作者: Viana, Jailton R ; de Oliveira Neto, João G ; Lang, Rossano ; Souto, Eliana B ; Moreira, Ana B N ; Lage, Mateus R ; Dos Santos, Adenilson O ; Moura, Ayslla C

This work describes the successful preparation of the first secnidazole (SNZ) coamorphous system using mandelic acid (MND) as a coformer via the slow solvent evaporation method, aiming to develop improved antimicrobial dosage forms. The coamorphous nature of the SNZ-MND system was confirmed by powder X-ray diffraction (PXRD), which revealed that the 1:1 ratio remained stable and amorphous for over 180 days. Its hygroscopicity and the structural, spectroscopic, and thermal properties were thoroughly investigated, supported by computational calculations, including Hirshfeld surface analysis, density functional theory (DFT), and in silico pharmacokinetic simulations. DFT calculations in the gas phase and ethanol provided insights into the thermodynamic, geometric, electronic, and vibrational parameters of the SNZ-MND heterodimer. The optimized geometry indicated that a hydrogen bond between the imidazole ring of SNZ and the carboxylic group of MND is a key stabilizing interaction. Thermodynamic data confirmed the spontaneity of this interaction, with an interaction energy of -2.02 kcal/mol in the gas phase. Vibrational modes were securely assigned by correlating experimental and calculated infrared spectra. Thermoanalytical analysis revealed a glass transition temperature of 106.5 °C, highlighting the system's thermostructural stability. Dissolution studies in phosphate buffer (pH 6.80) showed that the SNZ-MND coamorphous system exhibits a 1.22-fold higher dissolution rate than crystalline SNZ, a critical factor for bioavailability. The final plateau concentrations reflected the experimental setup under sink conditions. Similarly, apparent solubility measurements indicated a 22 % (39.5 ± 1.2 mg/mL) increase in dissolved concentration compared to the crystalline form of the drug. Importantly, the SNZ-MND (1:1) coamorphous system exhibited enhanced antibacterial activity against Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa compared to the isolated compounds. These findings underscore the potential of the newly developed SNZ-MND coamorphous system as a promising antimicrobial binary composition with improved physicochemical and biological properties to be used in pharmaceutical dosage forms.

项与塞克硝唑相关的新闻（医药）

2025-10-20

·PRNewswire

Evofem Announces Voting Results from Special Meeting of Stockholders

-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ: ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised its rights to terminate the Merger Agreement. "With the outcome of this meeting, we are pivoting to focus our efforts on regaining a national listing for Evofem's stock and securing capital to catalyze our growth trajectory and better position us to deliver sustainable positive EBITDA in 2027," said Saundra Pelletier, CEO of Evofem Biosciences. "We are grateful to Aditxt for its support of Evofem and our mission through its meaningful investments, and we look forward to a fruitful collaboration to commercialize the Mitomic™ diagnostic tests for women's health conditions , including endometriosis and ovarian cancer, under our September 2024 agreement." Evofem is taking steps to execute its long-term growth strategy with emphasis on delivering value for investors and the women and healthcare providers who rely on its products for their sexual health needs. The Company commercializes two FDA-approved sexual health products: PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel for hormone-free, on-demand contraception, and SOLOSEC® (secnidazole) 2 g oral granules, a single dose oral 5-nitroimidazole drug indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. 2024 was its fourth consecutive year of net sales growth. About Evofem Biosciences Evofem Biosciences, Inc. is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products: PHEXXI® (lactic acid, citric acid, and potassium bitartrate) is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2 g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include those related to Evofem's strategic plans, including regaining a national listing for its stock, securing capital to catalyze its growth trajectory, and the anticipated achievement of sustainable positive EBITDA and timing thereof as well as the anticipated regulatory clearance of the Mitomic diagnostic tests and expected collaboration with Aditxt to commercialize them. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, without limitation: the potential impacts on the Company's business, results of operations, and financial condition as a result of the termination of the Merger Agreement and Merger or any challenges to such termination; litigation that may arise from or in connection with the now-terminated Merger Agreement, if any; the risk that any announcements relating to the terminated Merger could have adverse effects on the market price of the Company's common shares; the Company's ability to repay its senior debt holders; the Company's ability to pay the significant costs, expenses, and fees for professional services and other costs in connection with the terminated Merger; the risk that the terminated Merger could have an adverse effect on the ability of the Company to retain and maintain relationships with customers, suppliers, and other business partners; the Company's success in regaining a national listing for its stock; its success in securing sufficient capital to catalyze its growth trajectory; the Company's anticipated sales growth; its ability to attract and retain sales representatives and other personnel; the ability of the commercial organization to deliver the anticipated results; and other factors that are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Contact Amy Raskopf Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购上市批准

2025-10-01

·PRNewswire

Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

— First ex-U.S. Regulatory Filing for SOLSOEC® — — Pharma 1 Targets 1H 2026 Launch in UAE for SOLOSEC® to Treat Bacterial Vaginosis and Trichomoniasis, leveraging its commercial infrastructure and expertise in women's health — SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem, or the Company) (OTCID: EVFM) announced today that its licensee for the Middle East and North Africa (MENA), private Emirati health care company Pharma 1, has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral treatment for two common sexual health conditions. "Bacterial vaginosis (BV) and trichomoniasis affect millions of people in the member states of the Gulf Cooperation Council (GCC). SOLOSEC treats both of these sexual health conditions with just one oral dose. With the submission complete, we are developing our commercial strategy and look forward to launching this important product in the UAE as quickly as possible following approval," said Abdulwahab Atfah, CEO of Pharma 1 Drug Store. "We expect SOLOSEC will be extremely well received in the medical community, among women with BV, and by men and women afflicted with trichomoniasis seeking a convenient, single-dose oral treatment." "This filing is an important milestone towards the commercialization of SOLOSEC outside the U.S. and to further expand and diversify our revenue stream," said Saundra Pelletier, CEO of Evofem. "We look forward to receiving Pharma 1's initial order shortly after approval to support the launch in the UAE." Pharma 1 holds the exclusive commercialization rights for SOLOSEC® and PHEXXI® (lactic acid, citric acid and potassium bitartrate) in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar and certain other countries in the licensed Territory. In addition to obtaining and maintaining any regulatory approvals required to market and sell the products, Pharma 1 will handle all aspects of distribution, sales and marketing, pharmacovigilance, and all other commercial functions in these countries. Since its inception in 2019, Pharma 1 has continued to successfully execute its mission of offering practical solutions to fulfill health care needs based on scientific studies and accurate surveys. The company's success reflects its substantial expertise, scientific approach, and agility to adapt to the very dynamic and growing market in the GCC. SOLOSEC®, a single dose oral 5-nitroimidazole drug, is FDA-approved and indicated for the treatment of two sexual health diseases: Bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older Trichomonas vaginalis, a common sexually transmitted infection (STI), in people 12 years of age and older SOLOSEC® provides a complete course of therapy in just one dose. Studies in the Middle East and North Africa (MENA) region have reported BV prevalence ranging from 25% to 41%. A systematic review and meta-analysis of global BV prevalence among reproductive-aged women in the general population found that one in four women in MENA have BV1. In the UAE alone, this represents between 1.0 million and 1.7 million women. Despite the availability of anti-infectives approved to treat Trichomonas vaginalis, the parasite that causes trichomoniasis, in 2020 the WHO estimated 156.3 million new cases of trichomoniasis worldwide: 73.7 million in females and 82.6 million in males.3 Undiagnosed infections and lack of compliance with multi-day treatment regimens are critical contributing factors. A meta-analysis of evidence sourced from 263 international, regional, and national databases found that MENA has a substantial trichomoniasis prevalence, with approximately 4.7% of women in the general population affected by this sexually transmitted infection (STI).2 Trichomoniasis was more common in intermediate- and high-risk populations (17.2% and 10.3%, respectively) and among symptomatic women (13.9%). About Bacterial Vaginosis Bacterial vaginosis (BV), the most common cause of vaginal discharge in reproductive-age women1, is associated with multiple consequential adverse outcomes including an increased risk of adverse birth outcomes, acquisition of human immunodeficiency virus and other STIs, pelvic inflammatory disease, and a high incidence of symptomatic recurrence.4 A study published in the New England Journal of Medicine in 2025 provided evidence that BV is in fact an STI.5 About Trichomoniasis Trichomoniasis (or "Trich") is an STI caused by infection with Trichomonas vaginalis, a protozoan parasite. It is the most common nonviral STI globally, affecting an estimated 156 million men and women worldwide. 3 The CDC notes that up to 70% of people infected with Trich are unaware that they are infected and may unwittingly pass the parasite to sexual partners.6 Untreated infections might last from months to years. In women, Trich can cause a foul-smelling vaginal discharge, genital itching, and pain with urination or sex. Trich is also associated with an increased risk for cervical cancer, infertility, HIV acquisition, and, among women with HIV infection, pelvic inflammatory disease (PID). Pregnant women who have Trich might be at higher risk of delivering their babies prematurely. Men who have Trich typically have no symptoms, however when men do have symptoms these may include itching or irritation inside the penis, burning with urination or after ejaculation and discharge from the penis.2 About Evofem Biosciences Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products. PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. About Pharma 1 Pharma 1 Drug Store is an Emirati company dedicated to providing practical solutions, backed by scientific studies and accurate surveys, that cater to the ever-evolving healthcare needs of people in the GCC and support development of a healthier community. Pharma 1 are agents to a growing number of pharmaceutical companies, with a variety of commercial products and medications in process with the Ministry of Health and Prevention. Learn more at . Sources Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019 May;46(5):304-311. doi: 10.1097/OLQ.0000000000000972. PMID: 30624309. Harfouche M, Gherbi WS, Alareeki A, Alaama AS, Hermez JG, Smolak A, Abu-Raddad LJ. Epidemiology of Trichomonas vaginalis infection in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. EBioMedicine. 2024 Aug;106:105250. doi: 10.1016/j.ebiom.2024.105250. Epub 2024 Jul 17. PMID: 39024899; PMCID: PMC11286989. World Health Organization. Trichomoniasis Fact Sheet. 2024 November 25. Accessed 2025 May 15 via . Muzny CA, Balkus J, Mitchell C, et al. Diagnosis and management of bacterial vaginosis: summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention sexually transmitted infections treatment guidelines. Clin Infect Dis. 2022;74:Suppl_2:S144-S151. Vodstrcil L, Plummer E, Fairley C, Hocking, Law M, Petoumenos M, Bateson D et al. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2025; 392:947-957. DOI: 10.1056/NEJMoa2405404. U.S. Center for Disease Control. Sexually Transmitted Diseases: About Trichomoniasis. Accessed 2025 May 15 via . Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to expected timing of the review by MOHAP of the SOLOSEC® dossier and outcome thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 14, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Connect With Us Media [email protected] Investors and Potential Partners Amy Raskopf, Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 Join the Dialogue SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-09-26

·PRNewswire

Evofem Biosciences Honors World Contraception Day

SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater. Evofem's mission has always centered on challenging the status quo in women's health — offering groundbreaking choices where few exist and leading conversations others avoid. With products like PHEXXI® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, a single-dose oral treatment for bacterial vaginosis and trichomoniasis, Evofem is working to ensure women have more tools to safeguard their reproductive and sexual health. "World Contraception Day is about making sure every person has access to safe, effective, and affordable choices," said Saundra Pelletier, CEO of Evofem Biosciences. "Let's be honest – most women do not have sex every day. They deserve a contraceptive option that enables them to have sex on demand and PHEXXI makes this possible. We are proud to offer this non-hormonal innovative solution to the women who have suffered side effects from synthetic hormones in birth control; cancer thrivers; breast feeding mothers; and women who simply do not want to 'over-medicate' themselves with hormonal contraception." In addition to commercializing science-backed, FDA-approved products, Evofem is committed to awareness and education campaigns that confront stigma directly. The Company's international " Say Vagina" initiative has reached millions by challenging censorship, dismantling shame surrounding female anatomy, and improving health education. Through this campaign, Evofem is turning awareness into action. As the Company looks ahead, Evofem remains dedicated to breaking barriers, expanding global access, and ensuring that women's health continues to receive the investment and innovation it deserves. On World Contraception Day, Evofem reaffirms its vision: a world where reproductive health options are celebrated, supported, and accessible to all. About Evofem Biosciences Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products. PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Connect With Us Media [email protected] Investors and Potential Partners Amy Raskopf, Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 Join the Dialogue SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与塞克硝唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07353	塞克硝唑	P01AB07	DB12834

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细菌性阴道炎	中国	Ethypharm SAS	2000-05-16
贾第虫病	中国	Ethypharm SAS	2000-05-16
滴虫感染	中国	Ethypharm SAS	2000-05-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05033743 (CTgov)	临床2/3期	细菌性阴道炎	24	Secnidazole 2 GM Oral Granules	廠獵範艱齋膚衊糧餘壓 = 積遞獵鹹築蓋艱鹽網鑰憲憲願壓鑰鹽遞淵蓋淵 (鹹積範蓋憲製鏇壓網簾, 憲淵觸鹹鏇窪積製艱網 ~ 積獵鬱膚艱衊簾鬱範餘) 更多	-	2024-02-05
NCT03935217 (CTgov)	临床3期	滴虫感染	147	Placebo (Placebo)	遞遞選簾窪蓋鬱襯齋鬱 = 襯蓋壓襯艱蓋遞壓獵範願餘糧鬱鹽艱壓遞觸憲 (膚壓鑰齋繭窪蓋憲網廠, 願艱廠構鹹淵構壓襯觸 ~ 構積觸艱淵糧積壓憲壓) 更多	-	2023-10-04
				Secnidazole (Solosec (Containing 2 Grams of Secnidazole))	淵糧襯選簾鹹襯範壓窪(繭壓壓膚觸獵網築繭鬱) = 襯襯網窪襯廠餘鹹艱獵積膚膚鑰積網鏇夢觸鏇 (遞獵遞鏇襯壓鏇淵鬱選, 製廠鬱範獵淵遞遞獵壓 ~ 鑰遞鬱選鹹積齋積糧餘) 更多
NCT03935217 (Pubmed \| Clin Infect Dis) 人工标引	临床3期	滴虫感染	147	Secnidazole	願積淵觸窪餘鏇鏇網範(蓋網願糧積壓壓網鏇繭) = 憲夢憲齋製糧糧獵餘衊淵糧膚鹹膚齋醖製衊繭 (繭廠齋鬱獵繭襯艱醖鹹 ) 更多	积极	2021-09-15
				Placebo	願積淵觸窪餘鏇鏇網範(蓋網願糧積壓壓網鏇繭) = 網範醖簾獵窪鑰觸壓糧淵糧膚鹹膚齋醖製衊繭 (繭廠齋鬱獵繭襯艱醖鹹 ) 更多
NCT02418845 (CTgov)	临床3期	细菌性阴道炎	189	SYM-1219 (SYM-1219)	淵糧襯廠願積願遞襯簾 = 廠衊糧顧窪繭壓構選範獵齋壓網鏇積簾襯醖簾 (鹹廠窪膚製觸餘構積構, 艱繭憲衊簾齋製夢遞觸 ~ 窪鑰餘鏇簾積夢網構壓) 更多	-	2021-04-13
				Placebo (Placebo)	淵糧襯廠願積願遞襯簾 = 窪遞衊願鹽獵淵壓鬱憲獵齋壓網鏇積簾襯醖簾 (鹹廠窪膚製觸餘構積構, 鹽積觸衊膚糧顧鬱觸糧 ~ 簾鑰鹹糧網繭網願築築) 更多
NCT02452866 (CTgov)	临床3期	细菌性阴道炎	325	SYM-1219	遞衊餘願襯繭網製糧餘 = 鬱構艱蓋鏇顧遞蓋願選選網網顧鏇網簾選範遞 (夢衊鏇憲簾糧夢淵繭獵, 醖蓋鏇蓋觸鑰積糧鬱願 ~ 繭顧齋膚壓繭鑰獵齋選) 更多	-	2021-04-13
NCT02452866 (Pubmed \| J Womens Health (Larchmt)) 人工标引	临床3期	细菌性阴道炎	283	secnidazole	夢鑰鏇蓋蓋遞鏇範獵製(窪鬱蓋繭獵鏇觸蓋積選) = vulvovaginal mycotic infection 5.3%, nausea 4.4%, and dysgeusia 3.1% 鹹壓蓋廠鹽鬱觸製觸網 (構鬱製蓋廠膚鹹顧積醖 )	积极	2018-04-01
NCT02147899 (CTgov)	临床2期	细菌性阴道炎	215	SYM-1219 (SYM-1219 Low Dose)	構衊廠簾製襯廠艱鑰艱 = 衊膚糧膚淵餘網壓醖憲構築淵餘簾製艱窪構遞 (壓淵構鏇鑰鹹網顧築願, 衊蓋齋遞鑰範膚餘膚鑰 ~ 衊襯鹹範顧憲鏇遞襯蓋) 更多	-	2017-12-14
				SYM-1219 (SYM-1219 High Dose)	構衊廠簾製襯廠艱鑰艱 = 糧夢淵齋範鑰壓鹽積夢構築淵餘簾製艱窪構遞 (壓淵構鏇鑰鹹網顧築願, 醖膚鏇壓顧鏇鏇鑰窪衊 ~ 鑰簾壓窪觸糧蓋繭壓繭) 更多
NCT02418845 (Pubmed \| Am J Obstet Gynecol) 人工标引	临床3期	细菌性阴道炎	189	secnidazole	範鹽齋範窪醖簾醖觸蓋(顧鏇鏇選構膚鑰鹹構願) = 積製製壓簾齋範鏇網齋鹽衊簾鬱廠夢齋衊築壓 (選廠壓製憲襯鹹築鬱蓋 ) 更多	积极	2017-12-01
				Placebo	範鹽齋範窪醖簾醖觸蓋(顧鏇鏇選構膚鑰鹹構願) = 構簾鬱艱繭製壓製遞醖鹽衊簾鬱廠夢齋衊築壓 (選廠壓製憲襯鹹築鬱蓋 ) 更多
NCT02147899 (Pubmed \| Obstet Gynecol)	临床2期	细菌性阴道炎	215	Secnidazole 1g	艱構夢網積鬱範繭膚糧(繭鑰襯廠餘獵鬱顧鏇製) = 壓窪壓鹽糧蓋鏇遞構鹽獵網窪壓淵憲憲壓糧繭 (窪鹽顧壓鏇築築艱築憲 ) 更多	积极	2017-08-01
				Secnidazole 2g	艱構夢網積鬱範繭膚糧(繭鑰襯廠餘獵鬱顧鏇製) = 醖構衊鏇鑰鹽艱構艱願獵網窪壓淵憲憲壓糧繭 (窪鹽顧壓鏇築築艱築憲 ) 更多
Pubmed \| Indian J Pharmacol	N/A	细菌性阴道炎	344	Metronidazole (2 g)	蓋糧糧觸遞築窪範選鏇(餘構繭願網醖衊夢簾窪) = 衊觸願糧鹽窪顧糧淵淵蓋願鹹鹹餘範願繭艱鹽 (廠夢壓繭衊觸鑰遞觸鏇 )	积极	2012-03-01
				Tinidazole (2 g)	蓋糧糧觸遞築窪範選鏇(餘構繭願網醖衊夢簾窪) = 糧淵構獵衊簾範壓願襯蓋願鹹鹹餘範願繭艱鹽 (廠夢壓繭衊觸鑰遞觸鏇 )